WO2020176757A1 - Compounds with ferroptosis inducing activity and methods of their use - Google Patents

Compounds with ferroptosis inducing activity and methods of their use Download PDF

Info

Publication number
WO2020176757A1
WO2020176757A1 PCT/US2020/020150 US2020020150W WO2020176757A1 WO 2020176757 A1 WO2020176757 A1 WO 2020176757A1 US 2020020150 W US2020020150 W US 2020020150W WO 2020176757 A1 WO2020176757 A1 WO 2020176757A1
Authority
WO
WIPO (PCT)
Prior art keywords
ciocycloalkyl
cgalkyl
independently
heteroaryl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2020/020150
Other languages
English (en)
French (fr)
Inventor
Chun Jiang
Anjali Pandey
Ruihong Chen
Biswajit Kalita
Athisayamani Jeyaraj DURAISWAMY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferro Therapeutics Inc
Original Assignee
Ferro Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/287,805 external-priority patent/US11098040B2/en
Priority to ES20712811T priority Critical patent/ES3013815T3/es
Priority to BR112021016833A priority patent/BR112021016833A2/pt
Priority to JP2021549973A priority patent/JP7704680B2/ja
Priority to CN202080028989.0A priority patent/CN114008024A/zh
Priority to CA3131385A priority patent/CA3131385A1/en
Priority to SG11202109035QA priority patent/SG11202109035QA/en
Priority to KR1020217030619A priority patent/KR20220012221A/ko
Priority to AU2020228056A priority patent/AU2020228056A1/en
Priority to EA202192122A priority patent/EA202192122A1/ru
Application filed by Ferro Therapeutics Inc filed Critical Ferro Therapeutics Inc
Priority to EP20712811.7A priority patent/EP3931183B1/en
Priority to MX2021010173A priority patent/MX2021010173A/es
Publication of WO2020176757A1 publication Critical patent/WO2020176757A1/en
Priority to IL285730A priority patent/IL285730A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Definitions

  • each R 13 is independently Ci-Cgalkyl or C 3 -Ciocycloalkyl
  • each R 5 is independently hydrogen, halo, -CN, -OH, -OR 8 , -NH 2 , -NHR 8 , -N(R 8 ) 2 , -S(0) 2 R 8 , -S(0)R 8 , -S(0) 2 N(R 7 ) 2 , -S(0)N(R 7 ) 2 , -NO 2 , -Si(R 15 ) 3 , -C(0)OR 6 , -C(0)N(R 7 ) 2 , -NR 12 C(0)R 8 , -OC(0)R 8 , -C(0)R 6 , -NR 12 C(0)0R 8 , -0C(0)N(R 7 ) 2 , -0C(0)CHR 8 N(R 12 ) 2 , Ci-Cgalkyl, C 2 -Cgalkenyl, Cz-Cgalkynyl, C 3 -Ciocycloalkyl, heterocyclyl, aryl, heteroaryl,
  • “Adamantyl” refers to tricyclo[3.3.1. l 3 7
  • R 2 is -Ci-C 2 haloalkyl, -C 2 -C 3 alkenyl, -C 2 -C 3 haloalkenyl, C 2 alkynyl, or -CH 2 0S(0) 2 -phenyl, wherein the Ci-C 2 haloalkyl and -C 2 -C 3 alkenylhalo are optionally substituted with one or two -CH 3 , and the C 2 alkynyl and phenyl are optionally substituted with one -CH 3
  • each R 6 is independently hydrogen, Ci-Cgalkyl, C 2 -Cgalkenyl, C 2 -Cgalkynyl, C 3 -Ciocycloalkyl, heterocyclyl, aryl, heteroaryl, -Ci-CgalkylC 3 -Ciocycloalkyl, -C 2 -CgalkenylC 3 -Ciocycloalkyl,
  • each R 8 is independently Ci-Cgalkyl, C 2 -Cgalkenyl, C 2 -Cgalkynyl, C 3 -Ciocycloalkyl, heterocyclyl, aryl, heteroaryl, -Ci-CgalkylC 3 -Ciocycloalkyl, -C 2 -CgalkenylC 3 -Ciocycloalkyl, -Ci-Cgalkylheterocyclyl, -C 2 -Cgalkenylheterocyclyl, -Ci-Cgalkylaryl, -C 2 -Cgalkenylaryl, -Ci-Cgalkylheteroaryl, or
  • each of ring A, X, R 1 , R 3 , R 4 , p, and q are independently as defined herein, and R 14 is halo.
  • ring A is aryl or heteroaryl
  • R 3 is halo, -NHR 8 , -S(0) 2 N(R 7 ) 2 , -C(0)OR 6 , -C(0)N(R 7 ) 2 , or heterocyclyl;
  • each R 11 is independently -O-G-Galkyl:
  • each R 12 is independently hydrogen, Ci-Cgalkyl or C3-Ciocycloalkyl
  • ring A is a bridged bicyclic ring selected from: wherein each R is attached to a carbon atom on the bridged bicyclic ring.
  • each R 5 is independently halo, -CN, -OH, Ci-Cgalkyl, C 2 -Cgalkynyl, or C3-Ciocycloalkyl.
  • each R 6 is independently hydrogen, Ci-Cgalkyl, C2-Cgalkenyl, or -Ci-CgalkylC3-Ciocycloalkyl; wherein each R 6 is independently further substituted with one to three R 11 .
  • a method for treating a malignant solid tumor in a patient in need thereof comprising administering an effective amount of a compound or composition provided herein to the patient.
  • the malignant solid tumor is a carcinoma.
  • the malignant solid tumor is a lymphoma.
  • the malignant solid tumor is a sarcoma.
  • the compounds described herein are used in combination with one or more of other (e.g., second therapeutic agent) therapeutic treatments for cancer.
  • the compounds can be used as monotherapy, or as further provided below, in a combination therapy with one or more therapeutic treatments, particularly in combination with one or more chemotherapeutic agents.
  • the compounds are used in combination with a second therapeutic agent, where the compounds are used at levels that sensitizes the cancer or cancer cell to the second therapeutic agent, for example at levels of the compound that do not cause significant cell death.
  • the compounds can be used in combination with radiation therapy, either to sensitize the cells to radiation therapy or as an adjunct to radiation therapy (e.g., at doses sufficient to activate cell death pathway).
  • the angiogenesis inhibitor is bevacizumab (Avastin), itraconazole, carboxyamidotriazole, TNP-470 (an analog of fumagillin), CM101, IFN-a, IF-12, platelet factor-4, suramin, SU5416, thrombospondin, a VEGFR antagonist, an angiostatic steroid plus heparin, cartilage-derived angiogenesis inhibitory factor (CDAI), a matrix metalloproteinase inhibitor, angiostatin, endostatin, 2-methoxyestradiol, tecogalan, tetrathiomolybdate, thalidomide, thrombospondin, prolactin, a a ⁇ 3 inhibitor, linomide, ramucirumab, tasquinimod, ranibizumab, sorafenib (Nexavar), sunitinib (Sutent), pazopanib (Votrient),
  • the lipoxygenase inhibitor may be a 15 -lipoxygenase inhibitor (see, e.g., Sadeghian et ah, Expert Opinion on Therapeutic Patents, 2015, 26: 1, 65-88).
  • the compounds can be formulated with a cyclodextrin or derivative thereof selected from carboxyalkyl cyclodextrin, hydroxyalkyl cyclodextrin, sulfoalkylether cyclodextrin, and an alkyl cyclodextrin.
  • the alkyl group in the cyclodextrin is methyl, ethyl, propyl, butyl, or pentyl.
  • a pharmaceutical composition of the compound is administered to a subject, preferably a human, at a therapeutically effective dose to prevent, treat, or control a condition or disease as described herein.
  • the pharmaceutical composition is administered to a subject in an amount sufficient to elicit an effective therapeutic response in the subject.
  • An effective therapeutic response is a response that at least partially arrests or slows the symptoms or complications of the condition or disease.
  • An amount adequate to accomplish this is defined as“therapeutically effective dose” or“therapeutically effective amount.”
  • the dosage of compounds can take into consideration, among others, the species of warm-blooded animal (mammal), the body weight, age, condition being treated, the severity of the condition being treated, the form of administration, route of administration. The size of the dose also will be determined by the existence, nature, and extent of any adverse effects that accompany the
  • a suitable dose can be from about 1 ng/kg to about 1000 mg/kg, from about 0.01 mg/kg to about 900 mg/kg, from about 0.1 mg/kg to about 800 mg/kg, from about 1 mg/kg to about 700 mg/kg, from about 2 mg/kg to about 500 mg/kg, from about 3 mg/kg to about 400 mg/kg, from about 4 mg/kg to about 300 mg/kg, or from about 5 mg/kg to about 200 mg/kg.
  • (S)-2-aminohexan-l-ol To a solution of (S)-2-aminohexanoic acid (30.0 g, 228.6 mmol, 1 eq) in THF (300 mL) at 0 °C was added lithium aluminiumhydride (1M in THF, 458 mL, 457.3 mmol, 2 eq) over a period of 1 h. Reaction mixture was warm to room temperature, then the mixture was stirred at 70 °C for 14 h under N2 atmosphere.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/US2020/020150 2019-02-27 2020-02-27 Compounds with ferroptosis inducing activity and methods of their use Ceased WO2020176757A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
MX2021010173A MX2021010173A (es) 2019-02-27 2020-02-27 Compuestos con actividad inductora de ferroptosis y métodos de uso.
KR1020217030619A KR20220012221A (ko) 2019-02-27 2020-02-27 페롭토시스 유도 활성을 갖는 화합물 및 이의 사용 방법
JP2021549973A JP7704680B2 (ja) 2019-02-27 2020-02-27 フェロトーシス誘導活性を有する化合物およびそれらの使用方法
CN202080028989.0A CN114008024A (zh) 2019-02-27 2020-02-27 具有铁死亡诱导活性的化合物以及使用其的方法
CA3131385A CA3131385A1 (en) 2019-02-27 2020-02-27 Compounds with ferroptosis inducing activity and methods of their use
SG11202109035QA SG11202109035QA (en) 2019-02-27 2020-02-27 Compounds with ferroptosis inducing activity and methods of their use
AU2020228056A AU2020228056A1 (en) 2019-02-27 2020-02-27 Compounds with ferroptosis inducing activity and methods of their use
ES20712811T ES3013815T3 (en) 2019-02-27 2020-02-27 Compounds with ferroptosis inducing activity and methods of their use
EA202192122A EA202192122A1 (ru) 2019-08-28 2020-02-27 Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
BR112021016833A BR112021016833A2 (pt) 2019-02-27 2020-02-27 Compostos com atividade indutora de ferroptose e métodos de seu uso
EP20712811.7A EP3931183B1 (en) 2019-02-27 2020-02-27 Compounds with ferroptosis inducing activity and methods of their use
IL285730A IL285730A (en) 2019-02-27 2021-08-19 Compounds with proptosis-inducing activity and methods of using them

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
USPCT/US2019/019854 2019-02-27
US16/287,805 US11098040B2 (en) 2018-02-28 2019-02-27 Compounds and methods of use
PCT/US2019/019854 WO2019168999A1 (en) 2018-02-28 2019-02-27 Compounds with ferroptosis inducing activity and methods of their use
US16/287,805 2019-02-27
US201962893092P 2019-08-28 2019-08-28
US62/893,092 2019-08-28

Publications (1)

Publication Number Publication Date
WO2020176757A1 true WO2020176757A1 (en) 2020-09-03

Family

ID=72238937

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/020150 Ceased WO2020176757A1 (en) 2019-02-27 2020-02-27 Compounds with ferroptosis inducing activity and methods of their use

Country Status (14)

Country Link
EP (1) EP3931183B1 (https=)
JP (1) JP7704680B2 (https=)
KR (1) KR20220012221A (https=)
CN (1) CN114008024A (https=)
AU (1) AU2020228056A1 (https=)
BR (1) BR112021016833A2 (https=)
CA (1) CA3131385A1 (https=)
EA (1) EA202192122A1 (https=)
ES (1) ES3013815T3 (https=)
IL (1) IL285730A (https=)
MX (1) MX2021010173A (https=)
SG (1) SG11202109035QA (https=)
TW (1) TW202045480A (https=)
WO (1) WO2020176757A1 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11040964B2 (en) 2019-02-27 2021-06-22 Ferro Therapeutics, Inc. Compounds and methods of use
US11098040B2 (en) 2018-02-28 2021-08-24 Ferro Therapeutics, Inc. Compounds and methods of use
WO2022042657A1 (en) * 2020-08-26 2022-03-03 Ferro Therapeutics, Inc. Compounds and methods of use
WO2023136472A1 (ko) * 2022-01-17 2023-07-20 포항공과대학교 산학협력단 Marh6 (marchf6) 조절제를 포함하는, 페로토시스 조절용 조성물 및 방법
WO2024015637A1 (en) * 2022-07-15 2024-01-18 Ferro Therapeutics, Inc. Glutathione peroxidase 4 (gpx4) inhibitors for the treatment of cancer
CN118047698A (zh) * 2024-01-30 2024-05-17 山东科巢生物制药有限公司 一种n-[(1r)-2-[1,1'-联苯]-4-基-1-(羟基甲基)乙基]氨基甲酸叔丁酯的制备方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10118890B2 (en) 2014-10-10 2018-11-06 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
CN114984019B (zh) * 2022-07-15 2023-08-22 山东中医药大学 一种铁死亡抑制剂化合物及在肝损伤修复领域的应用
CN117209521A (zh) * 2022-11-04 2023-12-12 台州道致科技股份有限公司 丙炔酰氯制备方法
CN116983310B (zh) * 2023-08-29 2024-04-30 南方医科大学南方医院 一种治疗肝癌的药物组合物及其应用
CN118994147B (zh) * 2024-07-18 2026-01-02 中国海洋大学 一种基于疏水标签的gpx4蛋白降解剂及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038563A2 (en) * 2000-11-08 2002-05-16 Lilly Icos Llc Condensed pyrazindione derivatives as pde inhibitors
WO2017120445A1 (en) * 2016-01-07 2017-07-13 The Broad Institute, Inc. Compounds and methods for increasing tumor infiltration by immune cells
WO2018118711A1 (en) * 2016-12-19 2018-06-28 The Trustees Of Columbia University In The City Of New York Small molecule ferroptosis inducers
WO2019168999A1 (en) * 2018-02-28 2019-09-06 Ferro Therapeutics, Inc. Compounds with ferroptosis inducing activity and methods of their use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3791870A1 (en) * 2013-12-02 2021-03-17 The Trustees of Columbia University in the City of New York Modulating ferroptosis and treating excitotoxic disorders
AU2016311426B2 (en) * 2015-08-26 2021-05-20 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to NTRK
JP2023509359A (ja) * 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
CN113336748B (zh) * 2021-04-12 2022-03-25 北京大学 一种gpx4蛋白降解剂及其制备方法和应用、一种抗肿瘤细胞药物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038563A2 (en) * 2000-11-08 2002-05-16 Lilly Icos Llc Condensed pyrazindione derivatives as pde inhibitors
WO2017120445A1 (en) * 2016-01-07 2017-07-13 The Broad Institute, Inc. Compounds and methods for increasing tumor infiltration by immune cells
WO2018118711A1 (en) * 2016-12-19 2018-06-28 The Trustees Of Columbia University In The City Of New York Small molecule ferroptosis inducers
WO2019168999A1 (en) * 2018-02-28 2019-09-06 Ferro Therapeutics, Inc. Compounds with ferroptosis inducing activity and methods of their use

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
"March's advanced organic chemistry : reactions, mechanisms, and structure", 18 May 2006, JOHN WILEY & SONS, INC., Hoboken, NJ, ISBN: 978-0-471-72091-1, article MICHAEL B SMITH ET AL: "ADDITION TO CARBON-HETERO MULTIPLE BONDS", pages: 1430 - 1434, XP055687809 *
"Physicians' Desk Reference", 2015, PDR NETWORK
"Reactions", vol. 1-40, 1991, JOHN WILEY, AND SONS
CAREYSUNDBERG: "Reaction and Synthesis", 2007, SPRINGER, article "Advanced Organic Chemistry"
COZZA ET AL., FREE RADICAL BIOLOGY AND MEDICINE, vol. 112, 2017, pages 1 - 11
FOSTER: "Deuterium Isotope Effects in Studies of Drug Metabolism", TRENDS PHARMACOL. SCI., vol. 5, no. 12, 1984, pages 524 - 527, XP025943358, DOI: 10.1016/0165-6147(84)90534-0
LI, J.J.: "Name Reactions", 2014, SPRINGER, article "A Collection of Detailed Mechanisms and Synthetic Applications"
SADEGHIAN ET AL., EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 26, no. 1, 2015, pages 65 - 88
SMITHMARCH: "March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 2001, JOHN WILEY, AND SONS
SONS: "Fieser and Fieser's Reagents for Organic Synthesis", vol. 1-15, 1989, ELSEVIER SCIENCE PUBLISHERS
VISWANATHAN ET AL., NATURE, vol. 547, 2017, pages 453 - 7

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11098040B2 (en) 2018-02-28 2021-08-24 Ferro Therapeutics, Inc. Compounds and methods of use
US11040964B2 (en) 2019-02-27 2021-06-22 Ferro Therapeutics, Inc. Compounds and methods of use
WO2022042657A1 (en) * 2020-08-26 2022-03-03 Ferro Therapeutics, Inc. Compounds and methods of use
WO2023136472A1 (ko) * 2022-01-17 2023-07-20 포항공과대학교 산학협력단 Marh6 (marchf6) 조절제를 포함하는, 페로토시스 조절용 조성물 및 방법
WO2024015637A1 (en) * 2022-07-15 2024-01-18 Ferro Therapeutics, Inc. Glutathione peroxidase 4 (gpx4) inhibitors for the treatment of cancer
CN118047698A (zh) * 2024-01-30 2024-05-17 山东科巢生物制药有限公司 一种n-[(1r)-2-[1,1'-联苯]-4-基-1-(羟基甲基)乙基]氨基甲酸叔丁酯的制备方法

Also Published As

Publication number Publication date
MX2021010173A (es) 2021-12-10
KR20220012221A (ko) 2022-02-03
JP7704680B2 (ja) 2025-07-08
AU2020228056A1 (en) 2021-09-16
BR112021016833A2 (pt) 2021-11-23
ES3013815T3 (en) 2025-04-15
CA3131385A1 (en) 2020-09-03
EA202192122A1 (ru) 2021-12-15
TW202045480A (zh) 2020-12-16
EP3931183B1 (en) 2025-02-12
EP3931183A1 (en) 2022-01-05
SG11202109035QA (en) 2021-09-29
IL285730A (en) 2021-10-31
JP2022522694A (ja) 2022-04-20
CN114008024A (zh) 2022-02-01

Similar Documents

Publication Publication Date Title
EP3931183B1 (en) Compounds with ferroptosis inducing activity and methods of their use
JP7348906B2 (ja) フェロトーシス誘導活性を有する化合物およびそれらの使用方法
US11040964B2 (en) Compounds and methods of use
US20240092739A1 (en) Compounds and methods of use
WO2021041539A2 (en) Compounds and methods of use
AU2019407650A1 (en) Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer
EP3768666A1 (en) Compounds and methods for ido and tdo modulation, and indications therefor
EP3929188A1 (en) Pd-l1 antagonist compound
WO2024015637A1 (en) Glutathione peroxidase 4 (gpx4) inhibitors for the treatment of cancer
AU2024374279A1 (en) Compounds for the degradation of mutant braf
US11013728B2 (en) Cyclin-dependent kinase 8 and/or 19 inhibitor
WO2021041536A1 (en) Benzimidazole and hydrogenated carbazole derivatives as gpx4 inhibitors
HK40067758A (en) Compounds with ferroptosis inducing activity and methods of their use
WO2025129116A1 (en) Compounds for the targeted degradation of smarca2

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20712811

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3131385

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021549973

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021016833

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2020228056

Country of ref document: AU

Date of ref document: 20200227

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20217030619

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020712811

Country of ref document: EP

Effective date: 20210927

ENP Entry into the national phase

Ref document number: 112021016833

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20210825

WWW Wipo information: withdrawn in national office

Ref document number: 285730

Country of ref document: IL